Ionis Pharmaceuticals, Inc.
IONS
Hisse Senetlerindeki Sıralama
#2664
Founded in 1989 and headquartered in Carlsbad, California, Ionis... Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
Hisse Fiyatı
$42.95
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$7.14B
Değişim (1 gün)
-2.65%
Değişim (1 yıl)
-41.23%
Ülke
US
Ticaret Ionis Pharmaceuticals, Inc. (IONS)
Kategori
Healthcare
Ionis Pharmaceuticals, Inc. (IONS) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -68.09%
Ionis Pharmaceuticals, Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -68.09%'dir. 2023 yılı sonunda şirketin faaliyet marjı -44.91% idi.
Ionis Pharmaceuticals, Inc. için 2000 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -68.09% | 1.07% |
| 2024 | -67.37% | 50.01% |
| 2023 | -44.91% | -35.86% |
| 2022 | -70.02% | 1,777.21% |
| 2021 | -3.73% | -84.19% |
| 2020 | -23.59% | -172.38% |
| 2019 | 32.59% | -418.57% |
| 2018 | -10.23% | -311.80% |
| 2017 | 4.83% | -136.15% |
| 2016 | -13.36% | -49.96% |
| 2015 | -26.70% | 19.78% |
| 2014 | -22.29% | -36.46% |
| 2013 | -35.08% | -48.06% |
| 2012 | -67.54% | -5.88% |
| 2011 | -71.76% | 60.97% |
| 2010 | -44.58% | 96.82% |
| 2009 | -22.65% | 85.96% |
| 2008 | -12.18% | -78.23% |
| 2007 | -55.94% | -79.85% |
| 2006 | -277.67% | 94.88% |
| 2005 | -142.48% | -48.47% |
| 2004 | -276.49% | 75.00% |
| 2003 | -157.99% | 149.31% |
| 2002 | -63.37% | -26.77% |
| 2001 | -86.54% | 11.21% |
| 2000 | -77.82% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 38.59% | -100.57% |
US
|
|
| -149.01% | -97.81% |
US
|
|
| 25.57% | -100.38% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.42% |
NL
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.